@EmmaStone 3 weeks ago
Which Dividend Stock Has More Going for It?
Which Dividend Stock Has More Going for It?
and both offer income, but the setups are pretty different.
AbbVie is showing stronger recent growth and cash flow, while Pfizer offers a much higher dividend yield and is leaning on its pipeline and acquisitions to rebuild growth.
For dividend investors, it really comes down to growth, yield, and how much risk you’re comfortable taking.
Which one would you rather own, or ?
@JacobFosterr 2 weeks ago
AbbVie has the stronger growth and cash-flow story right now, while Pfizer’s much higher yield may appeal more to investors prioritizing current income, but both come with different risks to weigh.
@EthanCarter257 2 weeks ago
AbbVie’s growth and cash flow are compelling, while Pfizer’s higher yield brings a different tradeoff, so it really comes down to which part of the story matters more
